관상동맥 중재적 디바이스 시장 : 제품 유형, 딜리버리 시스템, 용도, 판매 채널, 최종사용자별 - 세계 예측(2026-2032년)

The Coronary Interventional Devices Market was valued at USD 19.45 billion in 2025 and is projected to grow to USD 20.73 billion in 2026, with a CAGR of 5.79%, reaching USD 28.85 billion by 2032.

A concise portrayal of how clinical needs, aging populations, and procedural innovation are reshaping demand, device design, and care pathways in coronary interventions

Coronary interventional devices form the backbone of contemporary care for patients with obstructive coronary artery disease, providing direct mechanical and pharmacologic solutions that restore perfusion and reduce ischemic risk. These technologies span stents, balloon catheters, and a spectrum of atherectomy systems, each playing a distinct role across lesion types, vessel sizes, and procedural strategies. As clinicians pursue less invasive, more durable interventions, device performance, deliverability, and compatibility with adjunctive imaging and pharmacotherapy have become central determinants of procedural success and longer-term patient outcomes.

Epidemiologically, the prevalence of coronary artery disease remains elevated in many middle- and high-income populations, driven by aging demographics and persistent cardiometabolic risk factors. Consequently, the procedural mix is evolving: there is greater emphasis on complex lesion management, including calcified and bifurcation disease, which increases the demand for specialized devices and hybrid approaches. Simultaneously, shifts in care settings-from inpatient catheterization laboratories toward ambulatory surgical centers-are influencing device selection, inventory models, and logistics. These converging clinical, demographic, and care-delivery trends set the stage for rapid innovation and strategic recalibration among device manufacturers, health systems, and distributors.

From a regulatory and clinical-evidence perspective, iterative enhancements in device materials, drug elution platforms, and scaffold constructs have lowered complication rates and expanded indication envelopes. Emerging imaging modalities and physiology-driven decision tools are reshaping procedural algorithms, prompting device makers to integrate compatibility and adjunctive support into product roadmaps. Taken together, these factors underscore a dynamic environment in which clinical efficacy, economic value, and supply chain resilience define competitive differentiation.

How converging technological advancements, care setting migration, and evidence-driven regulatory expectations are redefining device development and adoption pathways

The coronary interventional landscape is being transformed by a confluence of technological maturation, shifting care delivery models, and evolving clinician expectations. On the technology front, drug eluting stent platforms continue to refine polymer chemistry, drug-release kinetics, and strut geometry to balance radial strength with endothelial healing. Concurrently, interest in bioresorbable concepts and drug-coated balloons has stimulated new clinical investigations and niche adoption where vessel preservation or restenosis biology warrants alternative approaches. These device-level shifts are complemented by advances in intraprocedural imaging and physiologic assessment; high-resolution imaging and physiology-guided workflows are increasingly used to optimize device selection and deployment, thereby reducing procedural variability.

Care delivery transformations are equally consequential. The migration of lower-risk percutaneous procedures to ambulatory surgical centers and specialty clinics is altering device procurement cycles, inventory strategies, and sterile processing requirements. As a result, manufacturers and distributors must prioritize compact packaging, rapid order fulfillment, and training resources tailored to diverse clinical environments. In parallel, digital health innovations-ranging from procedure planning software to remote proctoring-are enabling virtual training and performance feedback loops that accelerate clinician adoption of new devices. This digital integration also supports post-market surveillance and real-world evidence generation, which in turn inform iterative product improvements.

Finally, regulatory expectations and payer scrutiny are influencing product development strategies. There is stronger emphasis on demonstrable value, long-term safety, and comparative effectiveness, driving manufacturers to invest in both rigorous clinical programs and longitudinal registries. Taken together, these transformative shifts are forging a more connected ecosystem in which technical innovation, evidence generation, and delivery-channel optimization co-evolve to define competitive advantage.

An assessment of how 2025 tariff measures reshaped supply chains, procurement strategies, and manufacturing investment decisions across the coronary device ecosystem

Tariff policy enacted in and around 2025 introduced new cost considerations that ripple through sourcing strategies, procurement planning, and pricing decisions in the coronary interventional device space. Import duties and changes in harmonized tariff classifications affected a range of device components, including specialized alloys, polymeric compounds, and precision-engineered catheter elements, creating immediate cost pressure for manufacturers reliant on globalized supply chains. In response, many firms accelerated supplier diversification, sought nearshoring opportunities, and examined vertical integration options to reduce exposure to import levies and shipping volatility.

Beyond direct input-cost effects, tariffs influenced partner negotiations and distribution economics. Distributors with long-standing contracts adjusted margin structures to accommodate higher landed costs, while health systems re-evaluated formulary choices in light of total cost of ownership. These dynamics encouraged some purchasers to favor devices with simplified supply chains or to negotiate bundled pricing that encompassed ancillary disposables. Moreover, tariffs affected innovation timelines: capital that might have funded incremental R&D or commercialization activities in low-margin product lines was redirected to securing supply continuity and manufacturing resilience.

Crucially, the policy environment also catalyzed strategic investments in domestic manufacturing capabilities and quality-system enhancements. Firms investing in local production faced higher upfront costs but gained shorter lead times and greater control over regulatory compliance and traceability. As a result, an important consequence of tariff-induced disruption was a reconfiguration of risk management priorities across the industry, with procurement resilience, supplier transparency, and operational flexibility moving to the top of executive agendas.

Deep dive into product, clinical-user, and distribution segmentation that clarifies engineering trade-offs, adoption drivers, and supply chain implications for device portfolios

Understanding product and channel segmentation reveals where clinical demand, engineering focus, and commercial effort converge within coronary interventional portfolios. In the stent arena, distinctions among bare metal stent, bioresorbable vascular scaffold, and drug eluting stent illuminate divergent development priorities: bare metal constructs emphasize mechanical simplicity and cost-efficiency, whereas bioresorbable scaffolds prioritize temporary vessel support and eventual restoration of native physiology; drug eluting stents concentrate on drug-polymer interactions and alloy choice, with cobalt chromium, platinum chromium, and stainless steel variants each representing trade-offs in deliverability, radial strength, and radiopacity. Meanwhile, balloon catheter diversity-ranging from conventional balloon catheter designs through cutting balloon catheter, drug coated balloon catheter, and scoring balloon catheter-reflects the need to tailor tools to lesion morphology and to optimize drug transfer or plaque modification in calcified or restenotic segments.

Complementing stents and balloons, the atherectomy system segment is defined by distinct mechanistic approaches: laser atherectomy system solutions ablate tissue with precision energy, orbital atherectomy systems modify calcific plaque through centrifugal sanding, and rotational atherectomy systems selectively remove hard plaque using high-speed burrs. These modalities are selected based on lesion calcification patterns, vessel tortuosity, and operator familiarity, which in turn influences training and capital equipment strategies. From a user perspective, differences among ambulatory surgical centers, hospitals, and specialty clinics drive procurement behavior, procedural throughput expectations, and inventory management. Ambulatory settings typically emphasize disposability, rapid turnover, and compact sterile inventories, while hospitals balance a broader device mix with integrated support services; specialty clinics occupy niche positions where highly specialized devices and expertise are concentrated.

Distribution channels-direct relationships, distributor partnerships, and online ordering pathways-also determine market reach and service models. Manufacturers relying on direct sales often invest heavily in clinical education and local field teams, whereas distributor networks provide broad geographic coverage and logistical scalability; online channels add convenience and traceability but require robust quality assurances and regulatory vetting. Taken together, these segmentation layers animate product strategy, clinical engagement, and commercial execution across the coronary interventional landscape.

A strategic appraisal of how distinct regional healthcare structures and reimbursement environments drive differentiated adoption paths and commercialization tactics

Regional dynamics shape clinical practice patterns, reimbursement realities, and the pace of technology adoption in notable ways. In the Americas, procedural volumes and physician familiarity with advanced percutaneous solutions tend to support broad uptake of premium technologies, while consolidated payer systems and large integrated delivery networks drive structured procurement approaches and value-based contracting discussions. As a consequence, market entrants in this region focus on robust clinical data, efficient service models, and partnerships that align with hospital group procurement preferences.

Across Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable reimbursement pathways create a complex adoption landscape. While several European markets rapidly embrace evidence-backed innovations, other countries within the region prioritize cost-containment, which requires flexible pricing strategies and local reimbursement evidence. In addition, several nations within the region are implementing national registries and quality benchmarks that influence clinician adoption patterns and post-market surveillance expectations.

In Asia-Pacific, rising demand is propelled by expanding access to advanced cardiovascular care, increasing urbanization, and growing capacity in tertiary care centers. However, the region is not monolithic: advanced health systems in some economies demonstrate rapid uptake of next-generation devices, while emerging markets emphasize affordability and simplified logistics. Consequently, manufacturers pursuing Asia-Pacific expansion must calibrate product offerings to local clinical needs, regulatory timelines, and distribution capabilities, and they often combine clinical partnerships with localized training programs to build adoption momentum.

Insightful exploration of leading firms' strategic priorities showing how R&D focus, channel choices, and supply resilience are shaping competitive advantage

Industry participants are responding to clinical demand and competitive pressures through a combination of targeted R&D, strategic partnerships, and manufacturing optimization. Leading cardiac device companies have concentrated on enhancing stent deliverability, reducing thrombogenicity, and extending durability through advances in metallic alloys, polymer science, and antiproliferative agents. Others have supplemented core product lines by integrating imaging-compatible platforms and by supporting clinicians with digital tools for pre-procedural planning and intraoperative decision support. Parallel to product innovation, several firms have invested in supply-chain resilience by establishing regional manufacturing sites and by adopting multi-sourcing strategies for critical components.

Competitive dynamics also reflect differing go-to-market approaches. Some companies prioritize direct clinical engagement and long-term hospital partnerships, deploying dedicated field clinical specialists and robust training curricula to secure premium placements. Meanwhile, others leverage distributor networks and e-commerce channels to reach broader geographies and smaller care settings. Alliances between device manufacturers and technology firms are emerging, particularly in areas that link procedural devices with software-driven analytics and post-market surveillance capabilities. These collaborations aim to generate real-world evidence more efficiently and to support differentiated value propositions in reimbursement negotiations.

Collectively, company-level strategies reveal an industry balancing near-term operational resilience with longer-term innovation pipelines, translating scientific advances into reproducible clinical outcomes and scalable commercial models.

Action-focused recommendations for commercial, clinical, and supply-chain leaders to convert evidence and resilience into sustainable competitive advantage

Industry leaders should prioritize a set of coordinated actions to capture clinical value while managing operational risk. First, aligning product roadmaps with demonstrated clinical need and real-world evidence will be essential; this requires concentrated investment in registries and post-market studies that link device characteristics to patient-centered outcomes and health economic endpoints. Second, companies should operationalize supply-chain diversification by qualifying alternate suppliers, increasing inventory transparency, and exploring regional manufacturing partnerships to mitigate tariff and logistics risks. Third, close collaboration with clinicians and procedural teams must expand beyond initial product adoption to include comprehensive training, proctoring, and digital support tools that improve procedural consistency and outcomes.

Additionally, commercial teams should refine segmentation strategies to match distribution and pricing models with care settings-adapting packaging, service bundles, and procurement terms for ambulatory surgical centers, hospitals, and specialty clinics. Strategic partnerships with payers and health systems to develop outcome-based or bundled payment pilots can accelerate uptake for high-value technologies. Finally, leaders must invest in data capabilities that capture real-world performance, enabling iterative product improvements and stronger payer dialogues. By executing on these prioritized actions, organizations can strengthen clinical credibility, reduce exposure to external shocks, and accelerate sustainable growth.

A transparent mixed-methods research framework combining clinician interviews, regulatory and registry analyses, and cross-validated evidence synthesis to inform strategic decisions

The research adopted a mixed-methods approach to synthesize technical, clinical, and commercial insights across the coronary interventional domain. Primary data collection included structured interviews with interventional cardiologists, procurement leads, and device engineers to capture real-world procedural preferences, inventory practices, and unmet clinical needs. These qualitative inputs were triangulated with regulatory filings, peer-reviewed clinical trials, and procedural registry data to ensure alignment with published evidence and to identify emergent practice patterns. In addition, procurement and distribution experts provided operational context on contracting, logistics, and tariff-related impacts.

Analytical rigor was maintained through cross-validation of findings across multiple data sources, iterative hypothesis testing with subject-matter experts, and sensitivity checks where available. The methodology emphasized transparency in source attribution, explicit acknowledgment of regional heterogeneity, and a focus on outcome-relevant metrics rather than proprietary market sizing. Limitations include variable data granularity across regions and the evolving nature of regulatory decisions that may alter adoption timelines. To mitigate these constraints, the study prioritized longitudinal evidence and expert consensus to produce robust, actionable conclusions intended to inform strategic planning and operational decision-making.

Synthesis of how technological advances, clinical engagement, and operational resilience converge to define future success across coronary intervention markets

The cumulative analysis underscores a sector at the intersection of clinical necessity and rapid innovation, where device design, procedural imaging, and care-delivery models collectively determine value for patients and purchasers. Advances in stent technology, adjunctive balloons, and atherectomy modalities are expanding the armamentarium available to clinicians, while regional and policy dynamics shape the speed and character of adoption. Supply-chain resilience and evidence-generation capabilities have become decisive differentiators, particularly in an environment that includes new tariff considerations and variable reimbursement landscapes.

As the industry moves forward, successful stakeholders will be those who translate scientific progress into replicable clinical benefit, who align commercial models with diverse care settings, and who invest in resilient operations. Continuous engagement with clinicians, payers, and regulatory authorities will be essential to ensure that innovations meet both clinical and economic criteria for broad adoption. Ultimately, the path to sustained impact lies in pairing rigorous evidence with adaptable commercialization strategies that respect regional realities and evolving procedural practices.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coronary Interventional Devices Market, by Product Type

• 8.1. Coronary Stents
  • 8.1.1. Bare Metal Stents
  • 8.1.2. Drug Eluting Stents
  • 8.1.3. Bioresorbable Scaffolds
  • 8.1.4. Drug Coated Stents
• 8.2. Balloon Catheters
  • 8.2.1. Pre Dilatation Balloons
  • 8.2.2. Post Dilatation Balloons
  • 8.2.3. Drug Coated Balloons
  • 8.2.4. Cutting And Scoring Balloons
• 8.3. Guidewires
  • 8.3.1. Workhorse Guidewires
  • 8.3.2. Support Guidewires
  • 8.3.3. Specialty Guidewires
• 8.4. Catheters
  • 8.4.1. Guiding Catheters
  • 8.4.2. Diagnostic Catheters
• 8.5. Vascular Access And Closure Devices
  • 8.5.1. Introducer Sheaths
  • 8.5.2. Hemostatic Valves
  • 8.5.3. Vascular Closure Devices
• 8.6. Plaque Modification Devices
  • 8.6.1. Atherectomy Devices
  • 8.6.2. Intravascular Lithotripsy Systems
• 8.7. Thrombectomy And Embolic Protection Devices
  • 8.7.1. Aspiration Thrombectomy Devices
  • 8.7.2. Mechanical Thrombectomy Devices
  • 8.7.3. Embolic Protection Devices
• 8.8. Hemodynamic Support Devices
  • 8.8.1. Intra Aortic Balloon Pumps
  • 8.8.2. Percutaneous Ventricular Assist Devices
• 8.9. Imaging And Physiology Devices
  • 8.9.1. Intravascular Ultrasound Systems
  • 8.9.2. Optical Coherence Tomography Systems
  • 8.9.3. Fractional Flow Reserve Systems
  • 8.9.4. Instantaneous Wave Free Ratio Systems

9. Coronary Interventional Devices Market, by Delivery System

• 9.1. Over The Wire
• 9.2. Rapid Exchange
• 9.3. Fixed Wire
• 9.4. Steerable Systems
• 9.5. Sheathless Systems

10. Coronary Interventional Devices Market, by Application

• 10.1. Stable Coronary Artery Disease
• 10.2. Acute Coronary Syndromes
  • 10.2.1. ST Elevation Myocardial Infarction
  • 10.2.2. Non ST Elevation Acute Coronary Syndromes
• 10.3. Chronic Total Occlusion
• 10.4. Left Main Disease
• 10.5. Bifurcation Lesions
• 10.6. In Stent Restenosis

11. Coronary Interventional Devices Market, by Sales Channel

• 11.1. Direct Sales
• 11.2. Distributor Sales
• 11.3. Online Procurement Platforms

12. Coronary Interventional Devices Market, by End User

• 12.1. Hospitals
• 12.2. Cardiac Catheterization Laboratories
• 12.3. Ambulatory Surgical Centers

13. Coronary Interventional Devices Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Coronary Interventional Devices Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Coronary Interventional Devices Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Coronary Interventional Devices Market

17. China Coronary Interventional Devices Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Abbott Laboratories
• 18.6. AngioDynamics, Inc.
• 18.7. B. Braun Melsungen AG
• 18.8. Biotronik SE & Co. KG
• 18.9. Boston Scientific Corporation
• 18.10. Cardinal Health, Inc.
• 18.11. Cardiovascular Systems, Inc.
• 18.12. Cook Medical LLC
• 18.13. Edwards Lifesciences Corporation
• 18.14. Elixir Medical Corporation
• 18.15. Endologix LLC
• 18.16. iVascular S.L.U.
• 18.17. Johnson & Johnson Services, Inc.
• 18.18. Lepu Medical Technology (Beijing) Co., Ltd.
• 18.19. Medtronic plc
• 18.20. Merit Medical Systems, Inc.
• 18.21. MicroPort Scientific Corporation
• 18.22. QualiMed Innovative Medizinprodukte GmbH
• 18.23. Sahajanand Medical Technologies Limited
• 18.24. Shockwave Medical, Inc.
• 18.25. Siemens Healthineers AG
• 18.26. Teleflex Incorporated
• 18.27. Terumo Corporation